Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory trial of gastric microbiota eradication therapy for gastric intestinal metaplasia
jRCTs031230207Active, not recruiting
- Sponsor
- Yokohama City University
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vonoprazan, metronidazole and sitafloxacin in Intestinal metaplasia, sponsored by Yokohama City University. Primary endpoint: Improvement rate of histological intestinal metaplasia in gastric antrum. Started Jul 2023; status: active, not recruiting.
02
Drugs
vonoprazanmetronidazolesitafloxacin
03
Conditions
Intestinal metaplasia
Beyond the preview
Go deeper on jRCTs031230207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230207.